2016-12-12

[#DIV28SUPER] Experimental and Clinical Psychopharmacology

Dear Colleagues-
I am writing to you in my role as the incoming editor for APA's Experimental and Clinical Psychopharmacology. I have identified your division as one that may have an interest in the journal's content. I have appended the updated scope for the journal below, but would like to draw your attention to the new submission types that we will be accepting at the journal: brief communications (no more than 3000 words, excluding references; no more than 2 total figures or tables), case reports (no more than 2000 words; only 1 figure or table) and brief reviews (no more than 5000 words, excluding references). The journal will continue to accept original research reports (no word limit, but should typically be 4-8000 words, excluding references) and full reviews (no word limit).
I hope you will consider submitting relevant manuscripts to the journal and that you will share this information with any potentially interested colleagues.
Please feel free to contact me directly at william.stoops@uky.ed if you have questions about Experimental and Clinical Psychopharmacology.
Thank you,
Bill Stoops.

Journal Scope

Experimental and Clinical Psychopharmacology

 

 

 

Experimental and Clinical Psychopharmacology ® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology. The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs.

 

The journal publishes original reports and brief communications on the development and evaluation of pharmacotherapies for a range of mental health diagnoses, the influence of genetics and hormones on responses psychoactive drugs, the pharmacological management of pain, and brain imaging studies of the neural correlates of psychoactive drug effects.

 

 Rigorous preclinical and human laboratory studies,   as well as  controlled clinical trials of novel interventions, relevant to psychopharmacology and/or substance abuse, are particularly encouraged. The journal recommends that all submissions consider relevant biological variables (e.g., age, animal strain, sex) that may influence outcomes in study design and statistical analyses.

 

When appropriate (e.g., to provide initial clinical documentation of an emerging issue or topic in psychopharmacology and/or substance abuse), the journal will publish case reports. Case reports are expected to be thoughtful and thorough with attention paid to underlying etiology, behavioral, clinical, and laboratory findings. Any hypotheses should be supported by data and extant literature.

 

The journal will also include  integrative reviews, both full and brief, of advances in research on psychopharmacology and/or substance abuse. Full reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches. Brief reviews should provide a scholarly perspective on a circumscribed topic or a novel area that has a relatively small number of relevant research studies to consider. It is recommended that authors contact the editor prior to review preparation regarding suitability for the journal.

 

Each year, the journal will recognize individuals who are recipients of awards from APA Division 28 (Psychopharmacology and Substance Abuse).  Awardees will be invited to submit a full or brief review paper based on their award-winning research contributions.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2016-12-08

[#DIV28SUPER] Postdoc Opportunity

VTCRI Addiction Recovery Research Center Postdoc Opportunity

 

The Addiction Recovery Research Center of the Virginia Tech Carilion Research Institute has NIH-funded postdoctoral research associate opportunities in a state-of-the-art research facility. The postdoctoral associate will contribute to NIDA, NIAAA, NCI, and NIDDK funded research studies employing behavioral economics and neuro-economic approaches to address addiction, obesity, and other health behaviors using both human laboratory and clinical trial methodologiesThese positions will participate in studies using our International Quit & Recovery Registry and studies employing neuro-modulatory transcranial magnetic stimulation (TMS) and fMRI technologies. Research duties will involve authoring and co-authoring manuscripts, assisting with grant writing, and collaborating with investigators. The Addiction Recovery Research Center has an exceptional track record of helping postdoctoral associates further their careers as investigators. 

 

Appointment:  2-3 yrs.

 

Eligibility: Applicants should be interested in pursuing a career in addiction, obesity, and health behaviors research. Applicants should also be effective and productive writers and have research training in clinical, experimental, or cognitive psychology or related disciplines. Applicants must have completed a Ph.D. in psychology, behavior analysis, or a related field. Women and minorities are strongly encouraged to apply.

 

Benefits: Full-time annual salary, medical insurance coverage, and travel funds supported by NIH grants. Translational research training and career development opportunities are provided as part of this position.

 

For more information:  Contact Ms. Patsy Marshall (patsym@vtc.vt.edu).

 

To apply: Send cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to:  Dr. Warren K. Bickel c/o Ms. Patsy Marshall (patsym@vtc.vt.edu). Applications will be reviewed on an ongoing basis.

 

About us: The Addiction Recovery Research Center (ARRC) was established in 2011 as part of the Virginia Tech CarilionResearch Institute, an innovative partnership of Virginia Tech and Carilion Clinic. The facilities and research teams are world-class and focus on transdisciplinary research on the scientific underpinnings of health and a range of diseases and disorders. Virginia Tech Carilion Research Institute represents a new model for biomedical and behavioral science in which creative scientists can approach major problems with breadth and depth in a nurturing and intellectually challenging environment. 

 

About Roanoke, Virginia: Roanoke, Virginia is located in Southwest Virginia in the foothills of the Appalachian Mountains and accessible by the Blue Ridge Parkway. Roanoke is a vibrant community with an active downtown full of restaurants, theaters, museums, and a new amphitheater that is home to many seasonal festivals and music events. Roanoke also offers great opportunities for an active outdoor lifestyle with 30 miles of greenway connecting charming neighborhoods and beautiful parks along the Roanoke River.

 


Sent from my iPhone

2016-12-05

[#DIV28SUPER] LEAD Training Program


Training Opportunity for Underrepresented Early-Career Addictions Researchers!

We are happy to announce that the Learning for Early Careers in Addiction and Diversity (LEAD) Program is recruiting its new cohort!

The LEAD Program is an NIH-sponsored R25 training program that uses the NIDA CTN as a platform for providing research training to early-career investigators from underrepresented racial/ethnic minority groups conducting research in the substance use disorder (SUD) treatment and services field. This 2-year training program is based at the University of California, San Francisco (UCSF). Program scholars will spend 4 weeks at UCSF each summer and will develop and execute a pilot study at their home institution throughout the academic year. The program provides travel and housing funds as well as up to $25,000 to conduct the pilot study, which will serve as foundational data to support the submission of an R or K application. The program is directed by Carmen Masson, PhD, and James Sorensen, PhD, at UCSF.

 

The program recruitment flyer containing further information on eligibility criteria and selection process is attached. The deadline for applications is January 31, 2017. For any questions or to nominate a qualified candidate, please contact Rebecca Cook at rebecca.cook@ucsf.edu. Additional information can be found at http://psych.ucsf.edu/lead/.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
Component Lead
Research Methods
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2016-12-02

[#DIV28SUPER] Call for Nominations - Division 28 Awards

Dear Colleagues:  

Happy Holidays to everyone!

I am writing to encourage you to submit nomination materials for APA Division 28 Awards for the 2017 APA meeting in Washington, D.C.  Attached you will find the official call for nominations with the detailed instructions for each of the three awards:  Med Associates Brady-Schuster Award, Young Psychopharmacologist Award and Outstanding Dissertation Award.  These awards are an excellent way to recognize your outstanding colleagues in science- both the young and more seasoned!  The Awards Committee looks forward to seeing this year’s nominees.  The deadline for materials is January 15, 2017.  

The deadline is about 6 weeks away!  Don’t delay!

 

Regards,

 

Cathy Stanger

 

 

Catherine Stanger, Ph.D.

Associate Professor

Department of Psychiatry

Geisel School of Medicine at Dartmouth

46 Centerra Parkway

Suite 300, HB 7255

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-646-7023

Fax 603-448-5335

2016-12-01

[#DIV28SUPER] NIH HIV Research Priorities

Dear Colleagues,

 

On World AIDS Day, I thought you might be interested in a letter sent by APA and twenty-seven other organizations to HHS Secretary Burwell last February expressing concern about changing research priorities in the NIH Office of AIDS Research (OAR).  In the letter we urged OAR to establish a Working Group under the auspices of the OAR Advisory Council to develop guidelines for the prevention and treatment of HIV in those with substance use disorders.  Unfortunately, ten months later, OAR’s response indicates that is not likely to happen.  As indicated in yesterday’s Washington Post, as well as Dr. Volkow’s blog today, recent CDC figures suggest an increasing need for research in these populations.

 

 

Geoffrey K. Mumford, Ph.D. | Associate Executive Director for Government Relations

Science Directorate
American Psychological Association
750 First Street NE, Washington, DC 20002-4242
Tel: 202.336.6067 |  Fax: 202.336.6063

email: gmumford@apa.org | www.apa.org

   

 

P Most people consider the environment before printing their email.

 

 

 

 

 

[#DIV28SUPER] APA 2017 Convention Abstracts Due TODAY by 5pm EST!

Hello everyone,

A final reminder that convention abstracts are due today by 5pm EST.


Full details are available in the APA Call for Convention Proposals (PDF, 5.8MB).

The link to additional convention information is available here:  http://www.apa.org/convention/proposals.aspx

Warm regards,
Kelly Dunn, Ph.D.
---
Kelly Dunn, Ph.D.
Assistant Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P: 410-550-2254; F: 410-550-0030


[#DIV28SUPER] NYTimes: Hallucinogen Eases Depression in Cancer Patients, Studies Find

http://www.nytimes.com/2016/12/01/health/hallucinogenic-mushrooms-psilocybin-cancer-anxiety-depression.html?smprod=nytcore-iphone&smid=nytcore-iphone-share

Two studies used psilocybin to see if the drug could reduce depression and anxiety in cancer patients. The results were striking.


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org